The Carlyle Group Inc. 4.625% Subordinated Notes due 2061 (CGABL)vsVertex Pharmaceuticals Inc (VRTX)
CGABL
The Carlyle Group Inc. 4.625% Subordinated Notes due 2061
$16.15
0.00%
NONE · Cap: $16.14B
VRTX
Vertex Pharmaceuticals Inc
$446.83
-0.03%
HEALTHCARE · Cap: $107.89B
Smart Verdict
WallStSmart Research — data-driven comparison
VRTX leads profitability with a 35.5% profit margin vs 0.0%. VRTX earns a higher WallStSmart Score of 68/100 (B-).
CGABL
Avoid30
out of 100
Grade: F
VRTX
Strong Buy68
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for CGABL.
Margin of Safety
+53.1%
Fair Value
$952.53
Current Price
$446.83
$505.70 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Keeps 36 of every $100 in revenue as profit
Strong operational efficiency at 38.1%
Earnings expanding 61.4% YoY
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 22 in profit
Areas to Watch
0.0% revenue growth
0.0% earnings growth
ROE of 7.4% — below average capital efficiency
0.0% margin — thin
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : CGABL
CGABL has a balanced fundamental profile.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 35.5% and operating margin at 38.1%.
Bear Case : CGABL
The primary concerns for CGABL are Revenue Growth, EPS Growth, Return on Equity.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
CGABL profiles as a value stock while VRTX is a mature play — different risk/reward profiles.
VRTX is growing revenue faster at 7.8% — sustainability is the question.
VRTX generates stronger free cash flow (1.3B), providing more financial flexibility.
Monitor NONE industry trends, competitive dynamics, and regulatory changes.
Bottom Line
VRTX scores higher overall (68/100 vs 30/100), backed by strong 35.5% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
The Carlyle Group Inc. 4.625% Subordinated Notes due 2061
NONE · NONE · USA
The Carlyle Group Inc. 4.625% Subordinated Notes due 2061 offer institutional investors an attractive fixed-income opportunity backed by one of the world's premier investment firms with a strong track record in private equity, credit, and real assets. The competitive yield associated with these subordinated notes reflects Carlyle's robust market presence and strategic focus on growth and operational excellence. As the firm continues to broaden its global reach and optimize its portfolio management strategies, these notes are well-placed to deliver reliable long-term income within a diverse capital structure.
Visit Website →Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other NONE Stocks
Want to dig deeper into these stocks?